Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by stjjmacon Jan 15, 2012 8:01am
397 Views
Post# 19405102

RE: RE: Well Men?

RE: RE: Well Men?

Hockeylad, i agree with you on yor first 4 points but don't think they would halt to announce net pay only or mechanical issues as neither would be considered "material" to the stock. 

When they drilled Canaguay the previous management team made a huge mistake in communicating 100  feet of net pay but wouldn't be able to test for several months and then ended up with I believe only 5 feet of productive net pay.

Not terribly impressed with the new management team but I do think they are really trying to avoid the mistakes made by the previous team in setting unrealistic expectations.

I am guessing that we will have a release stating 2,000 - 3,000 boe which would be very good for QEI.

Be interesting to see if they halt it. In the 3 years I have been in and out of this stock I have never seen it halted.

Bullboard Posts